Shintaro Asako

Medmain Inc. is a company to develop and provide “PidPort”, a pathological AI analysis solution, with a corporate mission of "to create a world where medical services can be accessed with technology anywhere, anytime." “PidPort” is a product that enables the presentation of highly accurate and rapid analysis results by pathology AI developed by deep learning and the online pathological diagnosis such as remote pathological diagnosis. There is a worldwide shortage of "pathologists" who make diagnoses of patients by looking at their tissues and cells to determine whether there is cancer or not and decide the treatment plan, and this has led to serious delays in pathological diagnosis and large regional disparities. With our product “PidPort”, we aim to solve this problem and create a world in which patients can receive a high-quality pathological diagnosis immediately wherever they are.

Cygames, Inc. is a Japanese video game development studio established in 2011 by CyberAgent. From foundation the company produced mobile games, initially on the Mobage platform, and from 2013 on Android and iOS.

Delight Ventures is a JPY10B(USD100M) venture fund that invests in and incubates early-stage startups in Japan. It closely works with DeNA, a tech conglomerate that develops and operates a broad range of mobile and online services including games, pro-sports, e-commerce, and entertainment.

Official account of Uzabase, the provider of SPEEDA, FORCAS, NewsPicks, and other services.

Medmain Inc. is a company to develop and provide “PidPort”, a pathological AI analysis solution, with a corporate mission of "to create a world where medical services can be accessed with technology anywhere, anytime." “PidPort” is a product that enables the presentation of highly accurate and rapid analysis results by pathology AI developed by deep learning and the online pathological diagnosis such as remote pathological diagnosis. There is a worldwide shortage of "pathologists" who make diagnoses of patients by looking at their tissues and cells to determine whether there is cancer or not and decide the treatment plan, and this has led to serious delays in pathological diagnosis and large regional disparities. With our product “PidPort”, we aim to solve this problem and create a world in which patients can receive a high-quality pathological diagnosis immediately wherever they are.